Posted inInfectious Diseases news Respiratory
Amikacin Liposome Inhalation Suspension in Newly Diagnosed Mycobacterium avium Complex Lung Disease: Phase 3b ENCORE Trial
The ENCORE trial demonstrates that amikacin liposome inhalation suspension combined with multidrug therapy improves respiratory symptoms and culture conversion in newly diagnosed Mycobacterium avium complex lung disease patients.
